Press Releases

DAY HI:
DAY LOW:
VOLUME:

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Aug 08, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 8, 2019-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended June 30, 2019 .
Aug 01, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 1, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host a conference call with management to discuss the second quarter 2019 financial results, provide an update on the company's business, and discuss expectations for the future on
Jul 22, 2019
Recent pre-clinical data supports development of poziotinib for osimertinib resistance, as well as atypical mutations. Three new cohorts are currently open to patient enrollment in the ZENITH20 trial: Cohort 5 (Expansion Study), Cohort 6 (EGFR osimertinib failures), and Cohort 7 (Atypical EGFR or
Jun 20, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 20, 2019-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the appointment of Elizabeth Czerepak to the Board of Directors. Ms.
Jun 02, 2019
Integrated efficacy and safety results in 643 patients were consistent with individual trial results (ADVANCE and RECOVER) The integrated data demonstrated that eflapegrastim provided an absolute risk reduction of severe neutropenia of 6.5% compared to pegfilgrastim in Cycle 1 HENDERSON, Nev.
May 29, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--May 29, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the Jefferies 2019 Global Healthcare Conference being held in New York .
May 28, 2019
Enrollment of cohort 2 was completed six months ahead of schedule Cohort 2 had a target enrollment of 87 NSCLC patients with HER2 exon 20 insertion mutations Topline results from cohort 2 are expected in mid 2020 Topline results from cohort 1, which enrolled NSCLC patients with EGFR exon 20
May 16, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--May 16, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the 20th Annual B. Riley FBR Investor Conference being held in Beverly Hills, CA.
May 09, 2019
Topline results in the previously treated EGFR cohort (cohort 1) of the poziotinib ZENITH20 trial are expected in Q4 2019. Integrated data from the two Phase 3 ROLONTIS ® (eflapegrastim) clinical trials will be presented in a poster session at the American Society of Clinical Oncology 2019 annual
May 09, 2019
The Focused Interferon Therapeutics (FIT) platform is a proprietary targeted antibody-interferon fusion technology with potential broad application in oncology This asset purchase adds two innovative early-stage drug candidates to Spectrum’s existing pipeline and advances the oncology strategy
May 02, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--May 2, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host a conference call with management to discuss the first quarter 2019 financial results, provide an update on the company's business, and discuss expectations for the future on
Apr 02, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 2, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today that an overview of the company's business strategy and development-stage programs will be given at the H.C. Wainwright Global Life Sciences Conference being held in London .
Mar 15, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 15, 2019-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI) announced today that due to the U.S. Food and Drug Administration’s ( FDA ) request for additional manufacturing-related information for ROLONTIS, the company has voluntarily withdrawn its Biologics
Mar 13, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 13, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the
Mar 01, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 1, 2019-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today completed the sale of its portfolio of seven FDA -approved hematology/oncology products to Acrotech Biopharma
Feb 28, 2019
Poziotinib enrollment completed in previously treated EGFR cohort (cohort 1) of ZENITH20 trial; topline results are expected in Q4 2019 ROLONTIS ® (eflapegrastim) Biologics License Application (BLA) was submitted to the FDA Q4 Revenues were $29.4 million , including $28.0 million in product sales;
Feb 21, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 21, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host a conference call with management to discuss the fourth quarter and full year 2018 financial results, provide an update on the company's business, and discuss expectations for
Feb 07, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 7, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the Guggenheim Healthcare Talks Idea Forum | Oncology Day being held in New York .
Jan 17, 2019
Spectrum will receive $160 million in an upfront cash payment and up to $140 million in regulatory and sales-based milestones Staff size will be reduced by approximately 40 percent with the majority of impacted staff transitioning to Acrotech Spectrum will retain a core group of commercial talent
Jan 02, 2019
Results are expected in the second half of 2019 HENDERSON, Nev. --(BUSINESS WIRE)--Jan. 2, 2019-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today
Displaying 1 - 20 of 784